title: Flow cytometry-based assay to evaluate human serum MUC1-Tn antibodies.
abstract: Mucin-1 (MUC1) is a heavily O-glycosylated, transmembrane protein that is expressed on the apical surface of most secretory epithelia. In malignantly transformed epithelia, MUC1 has lost its apical distribution, is underglycosylated and is secreted into the circulation. Due to the underglycosylation of MUC1, cancer-specific MUC1-Tn/STn antigens, which are highly immunogenic, become exposed. We aimed at developing a system that allows detection of antibodies directed to the native form of MUC1 and the underglycosylated MUC1-Tn epitopes. To this end, we made use of the Chinese Hamster Ovary (CHO) ldlD cell line stably transfected with MUC1. This cell line has a glycosylation defect, which can be reversed by addition of different monosaccharides to the cell culture and enables the production of cells expressing the MUC1-Tn glycoforms. After validation with glycospecific antibodies, the CHO-ldlD MUC1 system was used to detect serum MUC1 and MUC1-Tn antibodies. Using this system, we could confirm the presence of MUC1-Tn antibodies in the serum of a patient vaccinated with a truncated MUC1 peptide. This indicates that the CHO-ldlD MUC1 system represents a flow cytometry-based technique to detect antibodies binding to the underglycosylated MUC1 protein. This cellular system is complementary to the previously published methods to detect MUC1 serum antibodies, since the antibodies to the native protein are evaluated and therefore it can be effectively used for MUC1 antibody monitoring in vaccination studies as well as for functional assays.
authors.affiliation: Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.
authors.forename: Catharina H M J
authors.initials: CH
authors.lastname: Van Elssen
authors.forename: Henrik
authors.initials: H
authors.lastname: Clausen
authors.forename: Wilfred T V
authors.initials: WT
authors.lastname: Germeraad
authors.forename: Eric P
authors.initials: EP
authors.lastname: Bennet
authors.forename: Paul P
authors.initials: PP
authors.lastname: Menheere
authors.forename: Gerard M J
authors.initials: GM
authors.lastname: Bos
authors.forename: Joris
authors.initials: J
authors.lastname: Vanderlocht
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000912:Antibodies, Neoplasm / Q000097:blood*; D000951:Antigens, Neoplasm / Q000737:chemistry* / Q000235:genetics; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy; D016466:CHO Cells; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D016022:Case-Control Studies; D006224:Cricetinae; D003412:Cricetulus; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006031:Glycosylation; D006801:Humans; D008969:Molecular Sequence Data; D018396:Mucin-1 / Q000737:chemistry* / Q000235:genetics / Q000276:immunology*; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D014162:Transfection; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; C060192:MUC1 protein, human; D018396:Mucin-1; D011994:Recombinant Proteins; D022223:Vaccines, Subunit